BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 23824677)

  • 1. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
    Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
    Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
    Adane ED; Herald M; Koura F
    Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion vancomycin for treatment of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.
    Fung L
    Ann Pharmacother; 2012 Oct; 46(10):e26. PubMed ID: 23032658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin dosing in children and young adults: back to the drawing board.
    Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
    Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Vancomycin Dose for Recommended Trough Concentrations in Pediatric Patients With Cystic Fibrosis.
    Amin RW; Guttmann RP; Harris QR; Thomas JW
    J Clin Pharmacol; 2018 May; 58(5):662-665. PubMed ID: 29319843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
    Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
    J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
    Frymoyer A; Guglielmo BJ; Hersh AL
    Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
    Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Gawronski KM; Goff DA; Brown J; Khadem TM; Bauer KA
    Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant Staphylococcus aureus.
    Stockmann C; Olson J; Rashid J; Lubsch L; Young DC; Hersh AL; Frymoyer A; Ampofo K; Liu X; Wang Y; Sherwin CMT; Zobell JT
    J Clin Pharmacol; 2019 Feb; 59(2):198-205. PubMed ID: 30371946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target.
    Bhongsatiern J; Stockmann C; Roberts JK; Yu T; Korgenski KE; Spigarelli MG; Desai PB; Sherwin CM
    Ther Drug Monit; 2015 Dec; 37(6):756-65. PubMed ID: 26562817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
    Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
    Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia.
    Suzuki Y; Kawasaki K; Sato Y; Tokimatsu I; Itoh H; Hiramatsu K; Takeyama M; Kadota J
    Chemotherapy; 2012; 58(4):308-12. PubMed ID: 23147106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.
    Frymoyer A; Hersh AL; Benet LZ; Guglielmo BJ
    Pediatr Infect Dis J; 2009 May; 28(5):398-402. PubMed ID: 19295465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy.
    Moffett BS; Morris J; Munoz F; Arikan AA
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1089-1097. PubMed ID: 30937470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children.
    Giachetto GA; Telechea HM; Speranza N; Oyarzun M; Nanni L; Menchaca A
    Pediatr Crit Care Med; 2011 Nov; 12(6):e250-4. PubMed ID: 21057350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus.
    Waterer G; Lord J; Hofmann T; Jouhikainen T
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31964790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.